|
1
|
Permuth-Wey J and Sellers TA: Epidemiology
of ovarian cancer. Methods Mol Biol. 472:413–437. 2009. View Article : Google Scholar
|
|
2
|
Seidman JD and Kurman RJ: Pathology of
ovarian carcinoma. Hematol Oncol Clin North Am. 17:909–925.
vii2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shih IeM and Kurman RJ: Ovarian
tumorigenesis: a proposed model based on morphological and
molecular genetic analysis. Am J Pathol. 164:1511–1518. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Seidman JD, Horkayne-Szakaly I, Haiba M,
Boice CR, Kurman RJ and Ronnett BM: The histologic type and stage
distribution of ovarian carcinomas of surface epithelial origin.
Int J Gynecol Pathol. 23:41–44. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Levanon K, Crum C and Drapkin R: New
insights into the pathogenesis of serous ovarian cancer and its
clinical impact. J Clin Oncol. 26:5284–5293. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang F, Niu G, Chen X and Cao F: Molecular
imaging of microRNAs. Eur J Nucl Med Mol Imaging. 38:1572–1579.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang F, Fu XD, Zhou Y and Zhang Y:
Down-regulation of the cyclin E1 oncogene expression by
microRNA-16–1 induces cell cycle arrest in human cancer cells. BMB
Rep. 42:725–730. 2009.PubMed/NCBI
|
|
10
|
Wang F, Song X, Li X, et al: Noninvasive
visualization of microRNA-16 in the chemoresistance of gastric
cancer using a dual reporter gene imaging system. PLoS One.
8:e617922013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Resnick KE, Alder H, Hagan JP, Richardson
DL, Croce CM and Cohn DE: The detection of differentially expressed
microRNAs from the serum of ovarian cancer patients using a novel
real-time PCR platform. Gynecol Oncol. 112:55–59. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yu SL, Chen HY, Chang GC, et al: MicroRNA
signature predicts survival and relapse in lung cancer. Cancer
Cell. 13:48–57. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zaman MS, Maher DM, Khan S, Jaggi M and
Chauhan SC: Current status and implications of microRNAs in ovarian
cancer diagnosis and therapy. J Ovarian Res. 5:442012. View Article : Google Scholar
|
|
14
|
Zhang L, Volinia S, Bonome T, et al:
Genomic and epigenetic alterations deregulate microRNA expression
in human epithelial ovarian cancer. Proc Natl Acad Sci USA.
105:7004–7009. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Iorio MV, Visone R, Di Leva G, et al:
MicroRNA signatures in human ovarian cancer. Cancer Res.
67:8699–8707. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nam EJ, Yoon H, Kim SW, et al: MicroRNA
expression profiles in serous ovarian carcinoma. Clin Cancer Res.
14:2690–2695. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gallagher MF, Flavin RJ, Elbaruni SA, et
al: Regulation of microRNA biosynthesis and expression in 2102Ep
embryonal carcinoma stem cells is mirrored in ovarian serous
adenocarcinoma patients. J Ovarian Res. 2:192009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wyman SK, Parkin RK, Mitchell PS, et al:
Repertoire of microRNAs in epithelial ovarian cancer as determined
by next generation sequencing of small RNA cDNA libraries. PLoS
One. 4:e53112009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Laios A, O’Toole S, Flavin R, et al:
Potential role of miR-9 and miR-223 in recurrent ovarian cancer.
Mol Cancer. 7:352008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Eitan R, Kushnir M, Lithwick-Yanai G, et
al: Tumor microRNA expression patterns associated with resistance
to platinum based chemotherapy and survival in ovarian cancer
patients. Gynecol Oncol. 114:253–259. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang N, Kaur S, Volinia S, et al: MicroRNA
microarray identifies Let-7i as a novel biomarker and therapeutic
target in human epithelial ovarian cancer. Cancer Res.
68:10307–10314. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mezzanzanica D, Bagnoli M, De Cecco L,
Valeri B and Canevari S: Role of microRNAs in ovarian cancer
pathogenesis and potential clinical implications. Int J Biochem
Cell Biol. 42:1262–1272. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kunej T, Godnic I, Ferdin J, Horvat S,
Dovc P and Calin GA: Epigenetic regulation of microRNAs in cancer:
an integrated review of literature. Mutat Res. 717:77–84. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xiao F, Zuo Z, Cai G, Kang S, Gao X and Li
T: miRecords: an integrated resource for microRNA-target
interactions. Nucleic Acids Res. 37:D105–D110. 2009.PubMed/NCBI
|
|
25
|
Huang da W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009.PubMed/NCBI
|
|
26
|
Vlachos IS, Kostoulas N, Vergoulis T, et
al: DIANA miRPath v. 20: investigating the combinatorial effect of
microRNAs in pathways. Nucleic Acids Res. 40:W498–W504. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Suh KS, Park SW, Castro A, et al: Ovarian
cancer biomarkers for molecular biosensors and translational
medicine. Expert Rev Mol Diagn. 10:1069–1083. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kriplani D and Patel MM:
Immunohistochemistry: a diagnostic aid in differentiating primary
epithelial ovarian tumors and tumors metastatic to the ovary. South
Asian J Cancer. 2:254–258. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Muraoka T, Soh J, Toyooka S, et al: The
degree of microRNA-34b/c methylation in serum-circulating DNA is
associated with malignant pleural mesothelioma. Lung Cancer.
82:485–490. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nadal E, Chen G, Gallegos M, et al:
Epigenetic inactivation of microRNA-34b/c predicts poor
disease-free survival in early-stage lung adenocarcinoma. Clin
Cancer Res. 19:6842–6852. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Suzuki R, Yamamoto E, Nojima M, et al:
Aberrant methylation of microRNA-34b/c is a predictive marker of
metachronous gastric cancer risk. J Gastroenterol. Aug
13–2013.(Epub ahead of print).
|
|
32
|
He XX, Chang Y, Meng FY, et al:
MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and
suppresses liver cancer cell growth in vitro and in vivo. Oncogene.
31:3357–3369. 2012. View Article : Google Scholar
|
|
33
|
Kong KL, Kwong DL, Chan TH, et al:
MicroRNA-375 inhibits tumour growth and metastasis in oesophageal
squamous cell carcinoma through repressing insulin-like growth
factor 1 receptor. Gut. 61:33–42. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fu X, Han Y, Wu Y, et al: Prognostic role
of microRNA-21 in various carcinomas: a systematic review and
meta-analysis. Eur J Clin Invest. 41:1245–1253. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yu X, Song H, Xia T, et al: Growth
inhibitory effects of three miR-129 family members on gastric
cancer. Gene. 532:87–93. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Karaayvaz M, Zhai H and Ju J: miR-129
promotes apoptosis and enhances chemosensitivity to 5-fluorouracil
in colorectal cancer. Cell Death Dis. 4:e6592013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu Y, Hei Y, Shu Q, et al: VCP/p97,
down-regulated by microRNA-129–5p, could regulate the progression
of hepatocellular carcinoma. PLoS One. 7:e358002012.PubMed/NCBI
|
|
38
|
Bray I, Tivnan A, Bryan K, et al:
MicroRNA-542–5p as a novel tumor suppressor in neuroblastoma.
Cancer Lett. 303:56–64. 2011.
|
|
39
|
Yamamoto S, Inoue J, Kawano T, Kozaki K,
Omura K and Inazawa J: The impact of mirna-based molecular
diagnostics and treatment of NRF2-stabilized tumors. Mol Cancer
Res. 12:58–68. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wu K, Hu G, He X, et al: MicroRNA-424–5p
suppresses the expression of SOCS6 in pancreatic cancer. Pathol
Oncol Res. 19:739–748. 2013.
|
|
41
|
Liang LH and He XH: Macro-management of
microRNAs in cell cycle progression of tumor cells and its
implications in anti-cancer therapy. Acta Pharmacol Sin.
32:1311–1320. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Makker A, Goel MM, Das V and Agarwal A:
PI3K-Akt-mTOR and MAPK signaling pathways in polycystic ovarian
syndrome, uterine leiomyomas and endometriosis: an update. Gynecol
Endocrinol. 28:175–181. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Nilsson EE and Skinner MK: Role of
transforming growth factor beta in ovarian surface epithelium
biology and ovarian cancer. Reprod Biomed Online. 5:254–258. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Slaby O, Svoboda M, Fabian P, et al:
Altered expression of miR-21, miR-31, miR-143 and miR-145 is
related to clinicopathologic features of colorectal cancer.
Oncology. 72:397–402. 2007. View Article : Google Scholar : PubMed/NCBI
|
